Central Government approves Umang Vohra as Chairman and Group CEO

Cohance Lifesciences (formerly Suven Pharmaceuticals) has received Central Government approval for Mr. Umang Vohra's appointment as Chairman and Group CEO.

Mon 12 Oct 2026

Approval Letter Date

8 October 2026

Approval Received by Company

12 October 2026

Director Identification Number

02296740

Government approval has come through

• The Ministry of Corporate Affairs (Central Government) has approved the appointment of Mr. Umang Vohra as Chairman and Group CEO of the Company.
• The approval is by a letter dated 8 October 2026, which the Company says it received on 12 October 2026.
• Mr. Vohra's director identification number is given in the update as 02296740.

Why the company is writing

Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) had earlier written to the exchanges about this appointment on 27 April 2026 and 26 June 2026. This letter is a continuation of those, telling shareholders that the Central Government approval linked to the appointment has now been received.

What it means for investors

A Chairman and Group CEO sits at the top of the company's management. This update is about a regulatory approval step for that leadership position being completed. The letter itself is described as an intimation for information and records, and is signed by the Company Secretary & Compliance Officer.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.